Corcept therapeutics exec Guyer sells $423,729 in shares

Corcept reported Q4 2025 revenue of $202.1M vs. $254.9M consensus and adjusted EPS $0.20 vs. $0.25, while FY2025 revenue was $761.4M, missing the revised guidance of $800M–$850M. Shares have fallen nearly 60% over six months to $33.82 (52-week high $117.33); H.C. Wainwright cut its price target from $67 to $60 but maintained a Buy. Chief Development Officer William Guyer sold 11,767 shares at a weighted average of $36.01 under a pre-arranged 10b5-1 plan and simultaneously exercised options to acquire 11,767 shares; director G. Leonard Baker Jr. purchased 100,000 shares, raising his holdings to 1,146,631. The company faces a securities class action related to an FDA rejection with lead plaintiff applications due April 21, 2026.

Analysis

The market has likely overshot on idiosyncratic risk, pushing implied volatility and financing costs materially higher for the issuer; that creates a window where capital providers and option sellers can extract premium while event risk clusters (regulatory, legal, earnings) remain unresolved. Forced selling and momentum-based fund flows can extend weakness beyond fundamentals for weeks to months, but they also create a convex recovery path if one or two positive catalysts land.

Second-order winners include arbitrage and activist players who can assemble concentrated positions at distressed prices while using options to fund a portion of carry; conversely, small-cap biotech capital providers and specialist lenders face elevated credit and covenant risk that could compress available working capital and amplify downside in a 3–12 month window. A sustained de-rating also raises the bar for future guidance — management will need to demonstrate credibility on both growth and margin stabilization to re-expand multiples.

Trade implementation should lean on volatility-aware structures: long-dated, defined-risk call spreads to capture asymmetric upside if settlement or regulatory clarity arrives, and short-dated put spreads or ratio structures to monetize near-term vol if you have a high-conviction view on no immediate downside catalyst. Keep pair or sector hedges to neutralize biotech beta; the path to recovery is binary and front-loaded into discrete catalysts over the next 6–12 months.

Key Decisions for Investors

• Buy CORT 24–36 month call spread (LEAPS): go long a near-ATM LEAPS call and sell a higher strike to fund ~50–70% of the premium. Position size 1–3% NAV; asymmetric payoff targets 2–4x if positive regulatory/earnings catalysts materialize within 12–36 months. Stop-loss: cut to 50% of cost if implied volatility collapses with no catalyst in 9 months.
• Short-dated CORT 30–90 day put spread to collect elevated IV premium: sell a near-term OTM put and buy a further OTM put to cap downside. Use proceeds to finance the put spread; this is a tactical 4–8 week trade with theta tailwind, suitable only if you expect no immediate binary downside event.
• Pair trade: short CORT vs long broad biotech (IBB or XBI) on a market-value neutral basis for 3–6 months to isolate idiosyncratic legal/regulatory risk. Target 0.5–1% NAV per leg; this reduces sector beta and profits if the name underperforms without broad sector weakness.
• Capital structure/credit watch: avoid unsecured equity-funded leverage on this name until legal and regulatory catalysts clear. If conviction is high, prefer buying equity through defined-risk option structures rather than outright margin; treat any recovery as catalyst-driven and re-assess covenants on corporate lenders within a 6–12 month horizon.